Dr. C. Cameron Yin has received her MD from Beijing Medical University and her PhD from the University of Wisconsin-Madison. She is currently a tenured professor in the Department of Hematopathology at the University of Texas MD Anderson Cancer Center and UT Graduate School of Biomedical Sciences. She is board certified by the American Board of Pathology in Anatomic Pathology, Clinical Pathology, Hematology and Molecular Genetic Pathology. In addition to clinical responsibilities on the Leukemia, Lymphoma and Molecular Diagnostic Laboratory services, Dr. Yin has been actively participating in multiple research projects in leukemia and lymphoma, which has led to about 150 research papers and over 20 book chapters. She serves as members of editorial boards for over 20 journals and ad hoc reviewers for over 30 journals. Her major research interests include molecular genetic aberrations in leukemia and lymphoma, development of molecular methodologies for the diagnosis, prognosis and minimal residual disease monitoring of hematopoietic neoplasms, mechanisms of resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia, as well as the role of immunoglobulin gene rearrangement in acute myeloid leukemia.
My laboratory is interested in mechanisms and therapy of cancers. In the past years, I have been working on different types of hematologic and solid cancers. Most lymphomas, but also an increasing number of solid tumors, are characterized by defined chromosomal translocations. The products of such translocations control tumor growth, confer precise biological characteristics to the tumors and can be targeted by specific therapies. In lymphoma, the translocations involving the Anaplastic Lymphoma Kinase (ALK) gene are characteristic of Anaplastic Large Cell Lymphoma (ALCL), but were recently found also in Non-Small Cell Lung Cancers (NSCLC) and other type of solid tumors. We have extensively studied the role of ALK in lymphoma and discovered multiple pathways essential to induce cellular transformation. By exploiting xenografts and mouse models for ALCL and NSCLC, and also neuroblastoma, we want to define relevant mechanisms of ALK-mediated transformation in vivo but also to validate therapeutic approaches to target ALK in such cancers. We are currently implementing innovative therapies such as ALK inhibitors, ALK-targeted siRNA and ALK-directed cancer immunotherapy. In this context, we developed a vaccination protocol that generates a strong ALK-specific immunization and seek to explore its potential use in clinical protocols.
Cancer Immunology, Lymphoma and Myeloma
Olfat M Hendy completed her MD at the age of 35 years from Clinical pathology deparetement, Menoufia Faclty of Medicine, Menoufia University, Egypt - and become professor of hematology & immunology at the same univerisity at 2009. She is the head of hematology unit at National Liver Institute- Menoufia University, Egypt. She has published more than 40 papers in reputed journals and has been serving as an editorial board member of repute. She was an supervisor on more than 53 MD and master thesis, and discussed more than 85 MD and master thesis. She is a membership in about 4 medical societies.
Hematology & Immunology
Biomedical Sciences and Pharmacy
Pathophysiology, genetics and epigenetics of MDS (role of transcription factors in regulation)